Neurocrine Biosciences, Inc. filed its quarterly report on Form 10-Q with the SEC on November 2, 2026, covering the three and nine months ended September 30, 2026, and reporting net income of $548.8 million for the nine-month period.

Key Highlights

  • Total revenues for the nine months ended September 30, 2026: $2,896.2 million, compared to $2,055.0 million in the same period of 2025, according to the filing.
  • Net product sales for Q3 2026: $1,119.0 million, up from $789.9 million in Q3 2025, as reported in the income statement.
  • Net income for nine months ended September 30, 2026: $548.8 million, compared to $324.9 million for the same period in 2025.
  • Diluted earnings per share for the nine-month period: $5.26, on weighted-average diluted shares outstanding of 104.3 million, per the filing.
  • Total assets as of September 30, 2026: $5,627.4 million, up from $4,631.5 million at December 31, 2025.
  • Intangible assets, net: $2,191.0 million as of September 30, 2026, compared to $4.7 million at December 31, 2025, reflecting significant acquisition activity during the period.
  • Common shares outstanding as of October 26, 2026: 101,218,643, per the cover page of the filing.

Neurocrine Biosciences Reports Revenue Growth and Expanded Asset Base in Third Quarter 2026

Neurocrine Biosciences, Inc. (NASDAQ:NBIX), a San Diego-based biosciences company, filed its Form 10-Q for the quarterly period ended September 30, 2026. According to the filing, total revenues for the nine months ended September 30, 2026 were $2,896.2 million, consisting of $2,884.3 million in net product sales and $11.9 million in collaboration revenues. For the three months ended September 30, 2026, total revenues were $1,122.7 million, compared to $794.9 million for the same quarter in 2025.

The filing reported operating income of $676.2 million for the nine-month period, and $331.3 million for the third quarter alone. Operating expenses for the nine months ended September 30, 2026 included research and development costs of $974.7 million and selling, general, and administrative expenses of $1,124.5 million. The filing also disclosed a gain on sale of business, net of transaction costs, of $28.6 million for the nine-month period. Amortization of acquired intangible assets totaled $51.5 million for the nine months ended September 30, 2026, versus $3.0 million in the comparable prior-year period.

The balance sheet showed a substantial increase in intangible assets to $2,191.0 million and goodwill to $500.6 million as of September 30, 2026, compared to $4.7 million and $6.1 million, respectively, at December 31, 2025, according to the filing. Total stockholders' equity grew to $3,878.7 million from $3,253.1 million at December 31, 2025. The statements of stockholders' equity reported that during the nine months ended September 30, 2026, the company repurchased 1.1 million shares with a charge of $158.1 million to retained earnings, while issuing 2.3 million shares under benefit plans for net proceeds of $67.1 million.

What Was Disclosed

Neurocrine Biosciences filed its Form 10-Q for the nine months ended September 30, 2026, disclosing revenues of $2,896.2 million, net income of $548.8 million, diluted earnings per share of $5.26, and a substantially expanded balance sheet reflecting significant intangible asset and goodwill additions during the period.